


RealRate

PHARMACEUTICAL 2022

VERTEX PHARMACEUTICALS INC MA Rank 13 of 475







PHARMACEUTICAL 2022



VERTEX PHARMACEUTICALS INC MA Rank 13 of 475



The relative strengths and weaknesses of VERTEX PHARMACEUTICALS INC MA are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of VERTEX PHARMACEUTICALS INC MA compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 439% points. The greatest weakness of VERTEX PHARMACEUTICALS INC MA is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 25% points.

The company's Economic Capital Ratio, given in the ranking table, is 248%, being 524% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	9,560,600
Cost of Goods Sold	904,200
Intangible Assets	1,402,200
Liabilities, Current	2,142,000
Liabilities, Non-Current	494,200
Other Assets	2,469,700
Other Compr. Net Income	84,400
Other Expenses	385,200
Other Liabilities	696,300
Other Net Income	-51,700
Property and Equipment	0
Research and Development	3,051,100
Revenues	7,574,400
Selling, General and Administrative Expense	840,100

Output Variable	Value in 1000 USD
Assets	13,432,500
Liabilities	3,332,500
Expenses	5,180,600
Stockholders Equity	10,100,000
Net Income	2,342,100
Comprehensive Net Income	2,384,300
Economic Capital Ratio	248%